HUTCHMED (China) Posts H1 Net Income USD 455 Million
07/08/2025 12:10
Aug 7 (Reuters) - HUTCHMED (CHINA) H1 NET INCOME USD 455 MILLION HUTCHMED (CHINA) H1 REVENUE USD 277.7 MILLION
Recent news on HUTCHMED (China)
See all newsSovleplenib Granted FDA Orphan Drug Designation
Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
Regulatory Filings Accepted for Review
Brief: HUTCHMED (China) Says Regulatory Filings For Orpathys Plus Tagrisso Accepted For Review In Europe And Japan
US FDA Grants Sovleplenib Orphan Drug Designation